Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sheesh you are correct I completely forgot .
10 days and it feels like I wrote in months ago hahaa , getting old I think , have a good day .
Disappointed in this I understand biotech is down but I cohort study results were good there is no reason for this to continue to fall , whether its true or not , makes me wonder if trial results were exaggerated made to sound better than they were .
Galectin have a advantage right now I believe as many of the larger companies are more focused on hepatitis c , looks like that will be old news in the next few years and more companies will focus on reversing advanced fibrosis , cirhossis
Lets hope Galectin is for real and the next cohort results continue to impress
nice read I agree what better news could we have received last , the rest of the biotechs are dragging down but this should rebound , cannot remember such low voulumes for days on end , not sure what that means
I agree I mean really if as 1st cohort went well there should be a rebound soon , most biotechs are down but the good ones should rebound .
1 st cohort successful how can this drop below $ 10 will not make sense
very steady for galt investors almost boring I think we are used to swings in either direction in a matter of hours
Very low volume last few days and price is quite steady no big spikes up or down
If results were better than expected why is this dropping , is it possible the results were made to look better than they really were as this does look strange
Much appreciated Tesla1 great information , looks like have something to look forward to , amazes me how this has been dropping this week
Galectin Therapeutics (NASDAQ:GALT) had its price objective hosited by MLV & Co. from $20.00 to $27.00 in a report released on Wednesday, American Banking & Market News reports. MLV & Co. currently has a buy rating on the stock.
Galectin Therapeutics (NASDAQ:GALT) traded down 2.28% during mid-day trading on Wednesday, hitting $13.72. The stock had a trading volume of 184,871 shares. Galectin Therapeutics has a 52 week low of $3.19 and a 52 week high of $19.11. The stock has a 50-day moving average of $15.84 and a 200-day moving average of $11.53. The company’s market cap is $300.9 million.
Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Friday, March 21st. The company reported ($0.15) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.03. On average, analysts predict that Galectin Therapeutics will post $-0.80 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Aegis raised their price target on shares of Galectin Therapeutics from $16.00 to $32.00 in a research note on Monday, February 10th. They now have a buy rating on the stock.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
To view MLV & Co.’s full report, visit MLV & Co.’s official website.
Sofosbuvir from gilead which went passed and cleared fda in 6 monthstook at least 3 years to go from phase 2 to fda approval
this is what I found February 5
sounds like from what I read below if all goes well end of 2016 phase 3 then I gather from that we are looking at towards end of 2018 approval
if it works well , is that right ? look I hope I am wrong I want to this to work probably more than most here as besides the money factor I have very close family members with advanced fibrosis desperate for something to look forward to .
Other than metastatic melanoma, GR-MD-02 is also studied in phase I for the treatment of nonalcoholic steatohepatitis (NASH) with advanced fibrosis. NASH is also known as fatty liver disease. Galectin Therapeutics completed enrolling patients in the first cohort of the phase I study on GR-MD-02 on Jan 13, 2014. Galectin Therapeutics might start a phase II study in late 2014 or early 2015 based on phase I study results and expects phase II top-line data in the first half of 2016 depending on the design of the study.
I am not trying to be rude but I cannot find ay data on the net that says if all goes well even with fast track this will go to fda for approval by next year sounds far to good to be true even if this does work
thefamilyman we are in phase one april 2014 now how it is possible to have fda approved by next year are you kidding me please I am not trying to be rude but what evidence do you have of this .
yes but to get this fda approved if it does work will not be any sooner than 5 years long way to go , they will need to test many many people
Phase 1 , 2 and 3 I think if all goes well and best case scenario would be 5 years
well most new drugs fail phase 1 so that may be why this has not taken off as quick as we all hoped still a risk of course always expect the un expected . Look at gilead for example jumped to $ 84 people were rushing to buy to avoid missing out dropped to $ 68 now slowly going up again .
Hi what is your prediction of price movement in the short term ?
Why the drop today ? you would at least think it would rise slightly but drop feels strange any thoughts ?
ask price on yahoo finance is 44.20
so we have 2 scenarios next week
week result will drop like a stone right like $ 5
good results around $ 20
is that about right ?
If you could somehow pick the flow of this stock you could make a handsome wage just trading this stock $ 12 ,$ 15 $ 18 , 19 , 14 , $ 15 sheesh
we are all on the same team here I have been fooled before with biotechs claiming this and that so just a little sceptical
lets hope for some good news come Monday or Tuesday .
Just seems strange how this stock can jump from 12 to 15 to 18 back to 13 back 16 etc in the space of a day or two sometimes feels like a pump and dump
I agree but biopsy would much more accurate than blood test .
I was told by a doctor he has seen patients come in with a advanced fibrosis reading fibrosure fibroscan blood test and be re tested a few months later with a totally different reading .
I am not bashing this stock as I would like a great result as I have shares in this company and also family members suffering from advanced fibrosis but I have my doubts if they will rely on a simple blood test .
This trial started a while back so biopsy should be used here
yes that is what I am saying I have a family member who had normal alt ast and was told he had advanced fibrosis after biopsy this is not as uncommon as many say .
Some people have slight elevations in alts ast and have far more damage to there livers .
I know for a fact that the only way to check
if fibrosis has regressed is by biopsy or fibroscan
Simple ALT & AST test is by means accurate as they
are very sensitive . ALT can go up noticeably by simply
knocking your leg and bruising . I have been told this by many
doctors and is true .
Why would he say this ? Adam Feuerstein Tweet: '$GALT: Mark The Date. Drug Data Are Coming and We're Selling Stock'
Read more: http://www.benzinga.com/news/14/03/4417727/adam-feuerstein-tweet-galt-mark-the-date-drug-data-are-coming-and-were-selling-st#ixzz2x0agSVVD
Hi thefamilyman , I have pasted details below , was not on a website had this emailed to me as I signed up to get any updates from this company a while back
Galectin prepares for secondary offering • 8:21 AM
•Galectin Therapeutics (GALT) files an S-3 for a $100M secondary offering of common stock plus 500,000 shares of common registered for sale by Richard Uihlein.
•The offering includes a sales agreement with MLV & Co. for up to $30M of potential time-to-time future sales.
The original item listed a "target price" of $16.50, but the price used was only a recent closing price, in compliance with SEC regulations. There is no definitive agreement with MLV on the $30M in sales.
Will this lower share price this news ?
•Galectin Therapeutics (GALT) files an S-3 for a $100M secondary offering of common stock plus 500,000 shares of common registered for sale by Richard Uihlein
That's fine all stocks are down today or most are
Darwanian great article I am very much looking forward to the news
Thanks for posting it .
this stock is at least not boring goes up and down so quickly lets hope it continues up
News not far away
Scam Stock sell while you still have your panties on
been a while to hear news should be in 3 weeks right ?
seems to be resistance at $ 15 hopefully will not drop below that or if it does not by much I am eagerly waiting news of trials if good news could shoot up to $ 25 quite quickly who knows
123tom you are correct has been falling I think I will buy at $15 as seems to be a good price
put in a buy bid $ 15 . 50 not accepted did drop to $ 15.19 maybe tomorrow many biotechs are very up and down but I notice galt goes up and down $ 1 to $ 2 in one session more than many others
dropped a little today , if it drops off a little into the $ 15 I think I should buy . Really should of bought 3 months ago but life is full of could of ,should of , but did 'nt
123tom your info is fantastic but what is your agenda not many try to help others with info please do not take it the wrong way I mean no offense . Do you believe that the product will reverse advance fibrosis and cirrhosis or is this just over hype which could drop like a stone in roughly a month when some cohort 1 information is released if proven not to work in a human trial ? . I would appreciate your thoughts 123tom . I am new to this forum but some great info .
This stock is nothing short of a joke pump and dump just a tease up a few pennies then down a a few more pennies some are making some great money with this